Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)11.26
  • Today's Change0.08 / 0.72%
  • Shares traded33.78m
  • 1 Year change-70.21%
  • Beta1.3807
Data delayed at least 15 minutes, as of Jul 05 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)18.31bn
  • Net income in HKD3.65bn
  • Incorporated2014
  • Employees12.74k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Keymed Biosciences Inc380.51m-386.16m9.47bn897.00--2.95--24.89-1.48-1.481.4411.470.09060.731426.14424,203.30-9.16---10.05--89.59---101.04--9.18--0.123--253.87---16.63------
InnoCare Pharma Ltd793.63m-678.35m9.96bn1.09k--1.13--12.55-0.4022-0.40220.47034.360.0731.393.39728,770.90-6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80--66.20--
RemeGen Co Ltd1.16bn-1.62bn19.27bn3.62k--3.15--16.66-3.01-3.012.156.870.18640.40054.31319,891.80-26.17-18.66-31.75-23.7576.4881.94-140.43-102.881.31-64.320.2682--40.16148.65-51.30--59.07--
Genscript Biotech Corp6.56bn-745.57m19.53bn6.94k--1.79--2.98-0.3539-0.35393.115.120.2837.595.45945,048.00-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
Akeso Inc4.86bn2.18bn33.68bn2.78k14.956.4915.036.922.602.605.816.000.61680.374915.981,750,867.0026.47-11.5931.40-13.8796.96--42.91-42.494.3919.180.3983--440.35337.43273.60--63.99--
Sichuan Kelun-Biotech Biophrmctcl Co Ltd1.66bn-616.96m36.41bn1.42k--14.31--22.00-2.78-2.787.5511.42------1,169,903.00--------49.28---37.27--2.47-34.900.0251--91.62--6.81------
WuXi Biologics (Cayman) Inc18.31bn3.65bn46.76bn12.74k13.401.108.782.550.840.844.2110.220.3215.043.021,436,813.006.738.288.4710.2540.0843.2520.9627.462.54--0.09390.0011.5646.38-23.0940.0720.32--
Beigene Ltd21.57bn-6.13bn126.42bn10.00k--4.59--5.86-4.55-4.5515.8119.300.47531.877.42---13.50-26.72-18.48-33.8574.7683.19-28.39-120.761.84--0.2339--73.6565.4756.00--33.46--
Data as of Jul 05 2024. Currency figures normalised to WuXi Biologics (Cayman) Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

21.09%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Oct 2022202.45m4.75%
The Vanguard Group, Inc.as of 06 Jun 2024140.00m3.28%
E Fund Management Co., Ltd.as of 31 Dec 2023130.16m3.05%
Schroder Investment Management Ltd.as of 31 May 202477.15m1.81%
Norges Bank Investment Managementas of 31 Dec 202370.08m1.64%
BlackRock Fund Advisorsas of 28 Jun 202469.48m1.63%
Schroder Investment Management (Hong Kong) Ltd.as of 31 Mar 202469.47m1.63%
BlackRock Advisors (UK) Ltd.as of 28 Jun 202464.70m1.52%
Hang Seng Investment Management Ltd.as of 07 Jun 202442.73m1.00%
GF Fund Management Co., Ltd.as of 31 Dec 202332.65m0.77%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.